



(11)

EP 3 638 696 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(48) Corrigendum issued on:
26.06.2024 Bulletin 2024/26

(45) Date of publication and mention
of the grant of the patent:
06.03.2024 Bulletin 2024/10

(21) Application number: **18732064.3**

(22) Date of filing: **18.06.2018**

(51) International Patent Classification (IPC):
C07K 16/28 ^(2006.01) **A61K 39/00** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
C07K 16/2875; A61K 31/706; A61K 39/39558;
A61K 45/06; A61P 35/02; A61K 2039/505;
C07K 2317/22; C07K 2317/24; C07K 2317/41;
C07K 2317/732; C07K 2317/734; C07K 2317/76;
C07K 2317/94 (Cont.)

(86) International application number:
PCT/EP2018/066144

(87) International publication number:
WO 2018/229303 (20.12.2018 Gazette 2018/51)

(54) **USE OF ANTI CD70 ANTIBODY ARGX-110 TO TREAT ACUTE MYELOID LEUKAEMIA**

ANWENDUNG VON ANTI CD70 ANTIKÖRPER ARGX-110, UM AKUTE MYELOID LEUKEMIE ZU
BEHANDELN

UTILISATION DE L'ANTICORPS ANTI-CD70 ARGX-110 POUR TRAITER LA LEUCÉMIE MYÉLOÏDE
AIGÜE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: **16.06.2017 GB 201709677**

(43) Date of publication of application:
22.04.2020 Bulletin 2020/17

(60) Divisional application:
24160069.1 / 4 389 142

(73) Proprietors:
• **argenx BV**
9052 Zwijnaarde (Ghent) (BE)
• **University of Bern**
3012 Bern (CH)

(72) Inventors:
• **LEUPIN, Nicolas**
B-9052 Gent (BE)
• **VAN ROMPAEY, Luc**
B-9052 Gent (BE)
• **DE HAARD, Hans**
B-9052 Gent (BE)
• **OCHSENBEIN, Adrian**
3032 Hinterkappelen (CH)
• **RIETHER, Carsten**
3012 Bern (CH)

(74) Representative: **Boult Wade Tennant LLP**
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP (GB)

(56) References cited:
WO-A1-2012/123586

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 638 696 B8

- **DEMPKE WOLFRAM C M ET AL:** "Second- and third-generation drugs for immuno-oncology treatment-The more the better?", **EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL**, vol. 74, 10 February 2017 (2017-02-10), pages 55-72, XP029933747, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2017.01.001
 - **J. JACOBS ET AL:** "CD70: An emerging target in cancer immunotherapy", **PHARMACOLOGY AND THERAPEUTICS.**, vol. 155, November 2015 (2015-11), pages 1-10, XP055289894, GB ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2015.07.007
 - **CARSTEN RIETHER ET AL:** "CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia", **JOURNAL OF EXPERIMENTAL MEDICINE**, vol. 214, no. 2, 28 December 2016 (2016-12-28), pages 359-380, XP055735891, US ISSN: 0022-1007, DOI: 10.1084/jem.20152008
 - **MAY KUNG SUTHERLAND ET AL:** "5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia", **MABS LANDES BIOSCIENCE**, vol. 24, 1 July 2010 (2010-07-01), pages 440-448, XP055096014, DOI: 10.4161/mabs.12203
- (52) Cooperative Patent Classification (CPC): (Cont.)
- C-Sets
A61K 31/706, A61K 2300/00;
A61K 39/39558, A61K 2300/00